Risk Level Remains at 4


This month’s allocation for the Value Model is Level 4, which calls for a mix of six stocks and 10 defensive positions. The defensive portion of the Model is composed of stocks, ETFs, bonds and cash.

When the stock market moved to a level of higher risk in October, I changed my risk level to 4, indicating the need for 10 defensive securities. My objective is to increase the defensive holdings in the Model when the stock market becomes overvalued, and decrease the defensive holdings in the Model when the market falls and becomes undervalued. I believe my strategy of increasing or decreasing the number of defensive positions will help you reduce your risk and enhance your profits.

If the Dow Jones Industrial Average, which is currently 17,888, falls to 16,373, my allocation mix will change to eight stocks and eight defensive positions, or Level 3. If the Dow rises to 19,212, my allocation mix will rise to Level 5, comprised of four stocks and 12 defensive positions.

This is an excerpt from Cabot Benjamin Graham Value Investor, which features the very best undervalued stocks to buy right now. Chief Analyst J. Royden Ward tells you exactly which undervalued stocks to buy and when to take profits. This advisory is ideal for conservative investors.

Subscribers' comments on Cabot Benjamin Graham Value Letter

Stock Picks


This stock could rise 50% before becoming fairly valued.

This hot technology company is growing like a weed, thanks to products that speed up cloud communications.

This stock is somewhat well known, but far from well loved.

Cabot Wealth Advisory

How to Find Great Growth Stocks in a Scary Market

By Paul Goodwin on October 21, 2016

Even in today’s scary market, there are great growth stocks out there. Here’s how to find them—and how to avoid the kind of losses that can haunt your portfolio.Read More >

Buy This Small-Cap Tech Stock as the Nasdaq Thrives

By Tyler Laundon on October 20, 2016

Technology stocks are thriving, as the Nasdaq has been outpacing the S&P 500 and the Dow for months. And one small-cap tech stock in particular is outperforming the industry’s big boys. Read More >

Is Allergan (AGN) Still an Undervalued Stock?

By Crista Huff on October 18, 2016

Five months ago, Allergan (AGN) was an undervalued stock with tons of growth potential. It's up 21% since then, but still has plenty of upside. Here's why.Read More >